3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other neoplasm
1
Conditions
Carcinoma, Non-Small-Cell Lung
606
Lung Neoplasms
190
Mesothelioma, Malignant
46
Adenocarcinoma of Lung
41
Mesothelioma
40
Neoplasms
31
Neoplasm Metastasis
28
Carcinoma
18
Colorectal Neoplasms
16
Small Cell Lung Carcinoma
14
Parkinson Disease 4, Autosomal Dominant Lewy Body
14
NSCLC
14
Adenocarcinoma
11
Melanoma
10
Lung Diseases
10
Brain Neoplasms
10
Adenocarcinoma, Bronchiolo-Alveolar
9
Thoracic Neoplasms
8
Non-squamous Non-small Cell Lung Cancer
8
Carcinoma, Bronchogenic
8
Respiratory Tract Neoplasms
7
Non-Squamous Non-Small Cell Lung Cancer
7
Neoplasms by Site
7
Bronchial Neoplasms
7
Respiratory Tract Diseases
6
Ovarian Neoplasms
6
Neoplasms by Histologic Type
6
Meningeal Carcinomatosis
6
Squamous Cell Carcinoma of Head and Neck
5
Solitary Fibrous Tumor, Pleural
5
Interventions
pembrolizumab
2
glutathione pegylated liposomal doxorubicin
1
Trastuzumab
1
Pemetrexed
1
Control Groups
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Processes
×
Pemetrexed
×
Thoracic
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled